Genmab — April 2023
-
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA
(teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-positive-topline-data -
small new trial for Daratumumab in Non-small Cell Lung Cancer With STK11/LKB1 Mutation (not by JNJ) https://clinicaltrials.gov/ct2/show/NCT05807048
-
Investeringspodcasten: Fokus på C25 og sidste udkald for SAS
https://www.proinvestor.com/boards/111969 -
Genmab sidst i udsendelsen.
-
Godmorgen
-
Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease (MOGAD) https://www.sciencedirect.com/science/article/pii/S2405650223000199?via%3Dihub
-
Umuligt at sige hvad der er indregnet, men enig med StockBull i, at opturen må forventes at være langt større ved sejr end nedturen ved tab. Jan har ligeledes flere gange på diverse CC´er sagt, at analytikerne ikke skal indregne noget før sejren er i hus. Så kan vi altid feste over et glas champagne, hvis det skulle ske !
-
Så mangler vi bare at Genmab kommer op i omdrejninger efter en forrygende Novo dag:-) Det vil gøre mega godt for min potefølje:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind